- Case Studies -

Expertise in Pre-Clinical Research
 

CASE STUDIES FROM
30+ YEARS OF DRUG DISCOVERY

NAEJA-RGM employs the most experienced medicinal chemists with decades of research experience and an impressive track record of success. Maintaining a small nucleus of drug discovery experts, NAEJA-RGM boasts a flexible and creative approach to scientific ingenuity.

CORE EXPERTISE

Pre-Clinical Development

Beta-Lactam-Antibiotics Drug-Discovery

CASE STUDY EXAMPLES FROM NAEJA

Case Study #1 - Antibacterial

Current Status

Market

  • β-Lactamase Inhibitor – Tazobactam
  • 4-Year SAR Program
  • Design, Synthesis, Screening
  • Marketed in combination with Piperacillin as Zosyn™
  • Annual revenues of $1 Billion

Case Study #2 - Non-Steroidal Anti-inflammatory

Current Status

Market

  • NSAID – Mofezolac (Disopain™)
  • 3-Year SAR Program
  • Design, Synthesis, Screening
  • Annual revenues of $100 million

Case Study #3 - Antibacterial

Current Status

Phase |

  • β-Lactamase Inhibitor – NAEJA-generated and developed project
  • 2-Year SAR Program
  • Design, Synthesis, Preclinical
  • Licensed by purchaser to 3rd party big pharma; est. deal value = $750 million

Case Study #4 - Central Nervous System

Current Status

Phase ||

  • Dopamine Receptor Partial Agonist
  • 3-Year extensive SAR Program
  • 4 other undisclosed targets
  • Synthesized several hundred analogues

Case Study #5 - Cardiovascular

Current Status

Phase ||b

  • ApoA-1
  • 3-Year SAR Program
  • Design, Synthesis, DMPK, animal efficacy

Case Study #6 - Anti-Fungal

Current Status

Market

  • Tavaborole (Kerydin™)
  • 3-Year SAR Program
  • Design, Synthesis, Screening